STOCK TITAN

PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

PAVmed (PAVM) reported preliminary third-quarter results and portfolio progress, including Medicare payments for Lucid Diagnostics’ EsoGuard esophageal precancer test. Lucid (LUCD) began receiving payments in October at the established Medicare fee-schedule rate. It performed 2,871 tests and recognized $1.2 million in revenue in Q3; October volume exceeded 1,800 tests.

PAVmed’s Q3 revenue was $41,000, versus $5,000 a year earlier. Its non-GAAP adjusted loss widened to $1.240 million from $446,000. Cash and equivalents, including restricted cash, totaled $8.9 million at September 30, including $5.3 million restricted. Veris completed its implantable monitor design freeze and began a 90-day animal study, targeting an early 2027 FDA submission. PortIO held an initial FDA meeting, with another scheduled for January 2027. Octeris completed its imaging probe and expects clinical validation enrollment to begin in January 2027.

Loading...
Loading translation...
12 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointLucid’s EsoGuard began receiving Medicare payments in October at its established Clinical Laboratory Fee Schedule rate.
  • Moderate pointLucid performed 2,871 EsoGuard tests and recognized $1.2 million revenue in Q3 2026.
  • Moderate pointLucid’s October EsoGuard volume reached a record more than 1,800 tests.
  • Moderate pointPAVmed cash, including restricted cash, increased to $8.9 million at September 30 from $1.5 million at year-end.
  • Minor pointVeris monthly patient enrollment at OSU-The James nearly doubled from July to September.
7 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Veris achieved design freeze and initiated a 90-day animal study in October, targeting early 2027 FDA submission.
  • Minor point. Forward-looking: it has not happened yet and may not happen.PortIO completed an initial FDA meeting in late October; a regulatory-pathway meeting follows in January 2027.
  • Minor pointOcteris completed its next-generation imaging probe, ready for clinical testing.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Octeris expects an initial FDA pre-submission package in November and clinical validation enrollment in January 2027.
  • Minor pointLucid published an 11,991-patient real-world EsoGuard study in the peer-reviewed journal Diagnostics.
  • Minor pointPAVmed Q3 revenue rose to $41,000 from $5,000 a year earlier.
  • Minor pointPAVmed nine-month revenue increased to $96,000 from $19,000 a year earlier.

Negative

  • Moderate pointPAVmed Q3 common-stockholder loss widened to $11.752 million from $6.328 million a year earlier.
  • Moderate pointPAVmed recorded a nine-month $3.422 million debt-extinguishment loss, versus $58,000 a year earlier. 4.3% of market cap
  • Minor pointPAVmed nine-month common-stockholder loss widened to $24.219 million from $1.942 million a year earlier.
  • Minor pointPAVmed Q3 operating expenses increased to $6.768 million from $4.849 million a year earlier.
  • Minor pointPAVmed nine-month operating expenses increased to $21.879 million from $15.022 million a year earlier.
3 minor points
  • Minor pointPAVmed Q3 non-GAAP adjusted loss widened to $1.240 million; per-share loss narrowed to $0.19 from $0.62.
  • Minor pointPAVmed nine-month non-GAAP adjusted loss widened to $4.759 million; per-share loss narrowed to $0.98 from $3.69.
  • Minor pointRestricted cash accounted for $5.3 million of PAVmed’s September 30 cash balance, versus $0.3 million at year-end.

Key Figures

PAVmed revenue: $41 thousand Operating expenses: approximately $6.8 million Non-GAAP adjusted loss: approximately $1.2 million; $(0.19) per common share +5 more
PAVmed revenue
$41 thousand
3Q26; table amounts are in thousands
Operating expenses
approximately $6.8 million
Three months ended September 30, 2026
Non-GAAP adjusted loss
approximately $1.2 million; $(0.19) per common share
3Q26
Cash and cash equivalents
$8.9 million, including restricted cash of $5.3 million
As of September 30, 2026
EsoGuard revenue
$1.2 million
Lucid Diagnostics, 3Q26
EsoGuard tests
2,871 tests
Lucid Diagnostics, 3Q26
October EsoGuard test volume
more than 1,800 tests
Record month for Lucid Diagnostics
Veris animal study and FDA submission
90-day GLP animal study; early 2027 FDA 510(k) submission
Study initiated in October; submission described as on track

Previous Earnings Reports

2 past events · Latest: Aug 14
Same Type 2 events
  1. Aug 14

    Q2 earnings update

    24h Move
    +9.7%

    Lucid reported EsoGuard revenue and tests while Veris advanced its monitor and PAVmed reported quarterly results.

  2. May 15

    Q1 earnings update

    24h Move
    +1.2%

    Lucid reported EsoGuard revenue and tests, while Veris advanced its monitor and PAVmed reported quarterly results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

medicare administrative contractor, 510(k), non-gaap, convertible securities
4 terms
medicare administrative contractor regulatory
"Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over that laboratory"
A Medicare Administrative Contractor is a private company hired to handle billing, payments, provider enrollment, and routine audits for Medicare in a specific region, acting like a local claims processor for a large government health plan. Investors care because these contractors influence how quickly and accurately healthcare providers get reimbursed, which affects providers’ cash flow, revenue timing and audit risk—key drivers of financial stability for companies that rely on Medicare payments.
510(k) regulatory
"early 2027 FDA 510(k) submission"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
non-gaap financial
"the Company's non-GAAP adjusted net loss was approximately $1.2 million"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
View in glossary
convertible securities financial
"loss on the issuance or modification of convertible securities"
Convertible securities are bonds or preferred shares that can be exchanged for a company’s common stock at a predetermined price or under specified conditions. They matter because they combine the steadiness of a loan or fixed dividend with the potential upside of ownership; like a safety‑net that carries a one‑time ticket to become a shareholder, they affect expected returns and can dilute existing stock if converted.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwide

Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission

PAVmed engaged with FDA on PortIO and Octeris

Conference call and webcast to be held today, November 13, at 8:30 AM EST

NEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the third quarter ended September 30, 2026.

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.

Conference Call and Webcast

The webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.

Business Update Highlights

"We're very encouraged by developments across the PAVmed portfolio," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value."

Highlights from the third quarter and recent weeks:

  • Lucid Diagnostics:
    • Began receiving payments from Medicare for the EsoGuard® Esophageal DNA Test in October. Lucid is submitting Medicare claims for tests performed at its Texas laboratory to Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over that laboratory, and is receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate.
    • Focused commercial efforts on expanding EsoGuard access among at-risk Medicare beneficiaries, who represent approximately 50% of the 30 million patients recommended for esophageal precancer testing by professional society guidelines.
    • Announced publication of an 11,991-patient real-world EsoGuard study in the peer-reviewed journal Diagnostics, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date, demonstrating the efficiency and scalability of the EsoCheck® Esophageal Cell Collection Device.
    • Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record month for EsoGuard test volume, with more than 1,800 tests.
  • Veris Health:
    • Monthly patient enrollment at OSU-The James grew throughout the quarter, nearly doubling from July to September, as the commercial phase of the strategic engagement continued to accelerate and the clinical rollout went live across most departments.
    • Achieved design freeze for the implantable physiological monitor and, in October, initiated the 90-day GLP animal study, keeping the device on track for an early 2027 FDA 510(k) submission.
  • PortIO:
    • Held an initial meeting with FDA on PortIO in late October, to be followed by an in-person pre-submission meeting in January 2027 focused on the device's regulatory pathway.
  • Octeris:
    • Completed Octeris' next-generation multimodal endoscopic imaging probe, which is ready for clinical testing. Octeris expects to submit its initial FDA pre-submission package this month, with enrollment in the University of North Carolina clinical validation study expected to begin in January 2027.

Preliminary Financial Results:

  • For the three months ended September 30, 2026, operating expenses were approximately $6.8 million, which included stock-based compensation expenses of $1.0 million. As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per common share.
  • PAVmed had cash and cash equivalents of $8.9 million, including restricted cash of $5.3 million, as of September 30, 2026, compared to cash and cash equivalents of $1.5 million, including $0.3 million of restricted cash, as of December 31, 2025.

PAVmed Non-GAAP Measures

  • To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
  • Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
  • Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
  • A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2026 and 2025 are as follows:



For the three months ended

September 30,


For the nine months ended

September 30,



2026


2025


2026


2025

(in thousands except per-share amounts)









Revenue


$           41


$             5


$           96


$           19

Operating expenses


6,768


4,849


21,879


15,022

Other (Income) Expense, net


6,308


1,167


(1,087)


(15,291)

Net (Income) Loss


13,035


6,011


20,696


(288)










Net income (loss) attributable to common stockholders


(11,752)


(6,328)


(24,219)


(1,942)

Preferred Stock dividends and deemed dividends


97


945


7,120


3,606

Net income (loss) as reported


(11,655)


(5,383)


(17,099)


1,664

Adjustments:









Depreciation and amortization expense1


19


22


58


87

Interest expense, net2


(2)


(2)


(26)


(8)

NCI ownership share of Interest and Depreciation
adjustments


(268)


—


(775)


—

EBITDA


(11,906)


(5,363)


(17,842)


1,743










Other non-cash or financing related expenses:









Stock-based compensation expense3


967


383


2,065


1,475

Operating expenses issued in stock1


140


52


2,091


155

Change in FV equity method investments


9,985


4,382


10,612


(5,979)

Preliminary Change in FV convertible debt2


(330)


100


(3,126)


349

Loss on debt extinguishment2


—


—


3,422


58

Change in fair value – warrant liability


—


—


(1,831)


—

Change in fair value – rights liability


(96)


—


(150)


—

Non-GAAP adjusted (loss)


$     (1,240)


$        (446)


$     (4,759)


$     (2,199)

Non-GAAP shares outstanding, basic and diluted


6,640


718


4,849


596

Non-GAAP adjusted (loss) income per share, basic and
diluted


$       (0.19)


$       (0.62)


$       (0.98)


$       (3.69)

1 Included in general and administrative expenses in the financial statements.

2 Included in other income and expenses.

3 Stock-based compensation ("SBC") expense is included in operating expenses and is
detailed as follows in the table below by category within operating expenses for the non-
GAAP Net operating expenses:

 


(in thousands except per-share amounts)


For the three months ended

September 30,


For the nine months ended

September 30,



2026


2025


2026


2025










Cost of revenue


$          158


$           55


$          377


$          133

Stock-based compensation expense3


—


—


—


—

Net cost of revenue


158


55


377


133










Sales and marketing


206


201


636


668

Stock-based compensation expense3


(17)


(13)


(30)


(59)

Net sales and marketing


189


188


606


609










General and administrative


4,482


3,505


15,489


11,557

Depreciation expense


(19)


(22)


(58)


(87)

Operating expenses issued in stock


(140)


(52)


(2,091)


(155)

Stock-based compensation expense3


(899)


(332)


(1,927)


(1,276)

Net general and administrative


3,424


3,099


11,413


10,039










Research and development


1,922


1,088


5,377


2,664

Stock-based compensation expense3


(51)


(38)


(108)


(140)

Net research and development


1,871


1,050


5,269


2,524










Total operating expenses


6,768


4,849


21,879


15,022

Depreciation and amortization expense


(19)


(22)


(58)


(87)

Operating expenses issued in stock


(140)


(52)


(2,091)


(155)

Stock-based compensation expense3


(967)


(383)


(2,065)


(1,475)

Net operating expenses


$       5,642


$       4,392


$      17,665


$      13,305

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.

For more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com. 

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-preliminary-third-quarter-2026-financial-results-302938900.html

SOURCE PAVmed Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PAVmed’s preliminary third-quarter 2026 financial results?

PAVmed reported $41,000 revenue and a $11.752 million loss attributable to common stockholders for the quarter ended September 30, 2026. A year earlier, revenue was $5,000 and the common-stockholder loss was $6.328 million. Non-GAAP adjusted loss was $1.240 million, or $0.19 per share.

How is Lucid Diagnostics receiving Medicare payments for EsoGuard?

Lucid submits Medicare claims for tests performed at its Texas laboratory to Novitas, the Medicare Administrative Contractor responsible for that laboratory. Payments began in October at EsoGuard’s established Clinical Laboratory Fee Schedule rate.

Where will Octeris conduct its planned clinical validation study?

Octeris expects enrollment in its University of North Carolina clinical validation study to begin in January 2027. Its completed next-generation multimodal endoscopic imaging probe is ready for clinical testing.

Keep reading